APTUK Position Statement for DHSC PGD Update

The Association of Pharmacy Technicians UK (APTUK), as the professional leadership body for pharmacy technicians, welcome the positive outcome of the DHSC consultation supporting the enabling of registered pharmacy technicians to supply and administer medications under patient group directions.

This is a landmark moment for patient care and will ensure pharmacy technicians are able to safely expand access to pharmacy services in a pressured healthcare landscape. During the COVID-19 pandemic it was also evident that pharmacy technicians and their potential were not able to be fully utilised to support delivery of essential frontline pharmacy services, such as vaccination.

To practise using a PGD, healthcare professionals must have completed any training outlined in the PGD and have been deemed competent and authorised by the provider organisation. As registered profession, pharmacy technicians must also uphold pharmacy professional standards stipulated by the regulator the General Pharmaceutical Council, and complete continued professional development relevant for their area of practice and role.

APTUK acknowledge that initially the powers will apply in England, Wales & Scotland only. This is because pharmacy technicians in Northern Ireland are not currently registered, therefore the planned changes will not enable pharmacy technicians in Northern Ireland to use PGDs. APTUK are assured that once pharmacy technicians in Northern Ireland become registered and regulated, further amendments may be made to permit this.

With this announcement, APTUK have also released the first in a series of supportive documents to educate and support pharmacy technicians with their scope of practice with such developments and changes to legislation.

Read the full article here

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article